Insmed Incorporated has appointed Samuele Butera as Senior Vice President, General Manager, Global Respiratory, effective today. In this new role, Mr. Butera will lead the company's Respiratory Therapeutic Area, reporting to Chair and CEO Will Lewis and serving on the Executive Committee. He joins from Johnson & Johnson, where he most recently served as President of Pulmonary Hypertension & Retina, overseeing a multi-billion-dollar business unit and the launch of OPSYNVI. His prior experience includes senior roles at Novartis, where he led the global launch of KYMRIAH, the first CAR-T therapy, and earlier positions at McKinsey & Company, Goldman Sachs, and the United Nations. Insmed stated that Mr. Butera's commercial expertise will be instrumental as the company continues the launch of BRINSUPRI, pursues a potential label expansion for ARIKAYCE, and advances its TPIP development program.
Insmed IncAppointment of senior executive with commercial expertise to lead respiratory business, supporting product launches and pipeline.
Johnson & Johnson
Novartis AG
Goldman Sachs Group Inc